Literature DB >> 19006185

Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations.

Jason P Covy1, Wuxing Yuan, Elisa A Waxman, Howard I Hurtig, Vivianna M Van Deerlin, Benoit I Giasson.   

Abstract

Mutations in LRRK2 are the single most common known cause of Parkinson's disease (PD). Two new PD patients with LRRK2 mutation were identified from a cohort with extensive postmortem assessment. One of these patients harbors the R793M mutation and presented with the typical clinical and pathological features of PD. A novel L1165P mutation was identified in a second patient. This patient had the classical and pathological features of PD, but additionally developed severe neuropsychological symptoms and dementia associated with abundant neurofibrillary tangles in the hippocampal formation; features consistent with a secondary diagnosis of tangle-predominant dementia. alpha-Synuclein-containing pathological inclusions in these patients also were highly phosphorylated at Ser-129, similar to other patients with idiopathic PD. These two PD patients also were characterized by the presence of occasional cytoplasmic TDP-43 inclusions in the temporal cortex, a finding that was not observed in three other patients with the G2019S mutation in LRRK2. These findings extend the clinical and pathological features that may be associated with LRRK2 mutations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19006185      PMCID: PMC2634827          DOI: 10.1002/mds.22096

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  46 in total

Review 1.  Alpha-synuclein and neurodegenerative diseases.

Authors:  M Goedert
Journal:  Nat Rev Neurosci       Date:  2001-07       Impact factor: 34.870

2.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

3.  The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method.

Authors:  B Pakkenberg; A Møller; H J Gundersen; A Mouritzen Dam; H Pakkenberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-01       Impact factor: 10.154

Review 4.  Neuropathology of Parkinson's disease.

Authors:  L S Forno
Journal:  J Neuropathol Exp Neurol       Date:  1996-03       Impact factor: 3.685

5.  alpha-Synuclein is phosphorylated in synucleinopathy lesions.

Authors:  Hideo Fujiwara; Masato Hasegawa; Naoshi Dohmae; Akiko Kawashima; Eliezer Masliah; Matthew S Goldberg; Jie Shen; Koji Takio; Takeshi Iwatsubo
Journal:  Nat Cell Biol       Date:  2002-02       Impact factor: 28.824

6.  A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease.

Authors:  B I Giasson; R Jakes; M Goedert; J E Duda; S Leight; J Q Trojanowski; V M Lee
Journal:  J Neurosci Res       Date:  2000-02-15       Impact factor: 4.164

7.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.

Authors:  M Baba; S Nakajo; P H Tu; T Tomita; K Nakaya; V M Lee; J Q Trojanowski; T Iwatsubo
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

8.  Autosomal dominant parkinsonism associated with variable synuclein and tau pathology.

Authors:  Z K Wszolek; R F Pfeiffer; Y Tsuboi; R J Uitti; R D McComb; A J Stoessl; A J Strongosky; A Zimprich; B Müller-Myhsok; M J Farrer; T Gasser; D B Calne; D W Dickson
Journal:  Neurology       Date:  2004-05-11       Impact factor: 9.910

9.  Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases.

Authors:  John E Duda; Benoit I Giasson; Meghann E Mabon; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2002-08       Impact factor: 10.422

10.  Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease.

Authors:  S Goldwurm; M Zini; L Mariani; S Tesei; R Miceli; F Sironi; M Clementi; V Bonifati; G Pezzoli
Journal:  Neurology       Date:  2007-01-10       Impact factor: 9.910

View more
  15 in total

1.  Lrrk2 localization in the primate basal ganglia and thalamus: a light and electron microscopic analysis in monkeys.

Authors:  H Lee; H L Melrose; M Yue; Jean-Francois Pare; M J Farrer; Y Smith
Journal:  Exp Neurol       Date:  2010-05-17       Impact factor: 5.330

Review 2.  Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.

Authors:  Susanne A Schneider; Roy N Alcalay
Journal:  Mov Disord       Date:  2017-11       Impact factor: 10.338

Review 3.  The neuropathology of genetic Parkinson's disease.

Authors:  Markos Poulopoulos; Oren A Levy; Roy N Alcalay
Journal:  Mov Disord       Date:  2012-03-26       Impact factor: 10.338

Review 4.  TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.

Authors:  Clotilde Lagier-Tourenne; Magdalini Polymenidou; Don W Cleveland
Journal:  Hum Mol Genet       Date:  2010-04-15       Impact factor: 6.150

Review 5.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

Review 6.  Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.

Authors:  Soumya Ray; Min Liu
Journal:  Future Med Chem       Date:  2012-09       Impact factor: 3.808

Review 7.  Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells.

Authors:  Liesel Goveas; Eugénie Mutez; Marie-Christine Chartier-Harlin; Jean-Marc Taymans
Journal:  Cells       Date:  2021-04-22       Impact factor: 6.600

8.  Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia.

Authors:  Beomsue Kim; Myung-Soon Yang; Dongjoo Choi; Jong-Hyeon Kim; Hye-Sun Kim; Wongi Seol; Sangdun Choi; Ilo Jou; Eun-Young Kim; Eun-Hye Joe
Journal:  PLoS One       Date:  2012-04-09       Impact factor: 3.240

9.  Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau.

Authors:  Jean-Marc Taymans; Mark R Cookson
Journal:  Bioessays       Date:  2010-03       Impact factor: 4.653

10.  LRRK2 phosphorylates novel tau epitopes and promotes tauopathy.

Authors:  Rachel M Bailey; Jason P Covy; Heather L Melrose; Linda Rousseau; Ruth Watkinson; Joshua Knight; Sarah Miles; Matthew J Farrer; Dennis W Dickson; Benoit I Giasson; Jada Lewis
Journal:  Acta Neuropathol       Date:  2013-10-11       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.